M&A / Deals Ipsen charts $1.75bn course for Kartos acquisition PharmaphorumIpsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.HematologyRead full story pharminent June 29, 2026 (Last updated: June 30, 2026) Pharmaphorum Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly’s Jaypirca receives CHMP positive opinion for CLL in EuropeNext: Viridian wins FDA approval for Lumvoa for thyroid eye disease Related Stories M&A / Deals Zymeworks cuts deal to buy Theravance for $929m in cash pharminent June 29, 2026 M&A / Deals Immunai and Boehringer partner to identify T-cell targets pharminent June 26, 2026 M&A / Deals Ionis grants Recordati rights to zilganersen for Alexander disease pharminent June 26, 2026
